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resumo A angiogénese é essencial à progressão tumoral. As terapias 
antiangiogénicas bloqueiam a angiogénese e causam regressão dos vasos 
sanguíneos, o que leva a um aumento da hipóxia nos tumores. A hipóxia é 
responsável por diversos efeitos na biologia tumoral, entre os quais, a 
seleção de células cancerígenas mais agressivas e mais resistentes às 
terapias. 
Com este projeto pretendemos descobrir o mecanismo molecular envolvido 
na resistência à combinação de bevacizumab e cetuximab e também 
encontrar interações de letalidade sintética com hipóxia. 
Os nossos resultados mostram que: a hipóxia induz resistência à inibição de 
EGFR em células WT4 de cancro coloretal; o HIF1α não é responsável pelo 
fenótipo de resistência; a hipóxia ativa RAS em células WT4 de cancro 
coloretal; os inibidores de MEK aumentam a sensibilidade aos inibidores de 
EGFR em hipóxia e as citoquinas parecem estar envolvidas na ativação de 
RAS em hipóxia. Identificámos ainda quatro genes que são potenciais 
candidatos a terem letalidade sintética com hipóxia. 
Estes resultados têm uma grande importância clínica e biológica e podem 
conduzir a melhores terapias combinatórias, contribuindo para melhorar os 
atuais tratamentos de pacientes com cancro coloretal e podem ainda levar 
à descoberta de biomarcadores de resposta a terapias antiangiogénicas. 
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abstract Angiogenesis is essential for tumor progression. Antiangiogenic therapies 
block angiogenesis and cause vessel regression, which leads to an increase 
of tumor hypoxia. Hypoxia is responsible for many effects in tumor biology, 
among which, the selection of cells that are more aggressive and more 
resistant to cancer therapies.  
In this project we aim to get some molecular insight on the mechanism(s) 
underlying the resistance to the combination of bevacizumab and cetuximab 
and to find synthetic lethal interactions with hypoxia. 
Our results show that: hypoxia induces resistance to EGFR inhibition in WT4 
CRC cell; HIF1α is not driving the resistance phenotype; hypoxia activates 
RAS in WT4 CRC cells; MEK inhibitors increase the sensitivity to EGFR 
inhibitors in hypoxia and cytokines seem to be involved in the activation of 
RAS in hypoxia. We also identified four genes as potential candidates to be 
synthetic lethal with hypoxia. 
Our findings are of great clinical and biological significance and may lead to 
better combination therapies, improving current treatments for CRC 
patients and may also lead to the discovery of biomarkers of response to 
antiangiogenic therapies. 
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1. Introduction 
1.1. Cancer 
1.1.1. Cancer basics 
Cancer is a complex collection of distinct genetic diseases. It is characterized by an 
abnormal, continued, uncontrolled and damaging growth of cells, with the potential to 
invade or spread to other parts of the body, that differ structurally and functionally from 
the normal cells from which they developed.1–4 
Cancer is the result of genetic and epigenetic alterations in the DNA, specifically 
those that cause mutations in proto-oncogenes and tumor suppressor genes.1,5,6 Many 
different factors initiate changes in cells that lead to cancer, but they are usually divided in 
two groups: environmental and lifestyle conditions (e.g., chemicals, radiation, viruses, 
pollution, smoking, diet, alcohol, sun exposure, stress and physical inactivity) – accounting 
for 90 to 95% of cases; and inherited genetic defects – accounting for 5 to 10% of cases.1,6–
9 
Consistent with Darwinian principles, cancer evolves through a series of 
accumulated random mutations followed by the clonal selection of cells that can survive 
and proliferate under circumstances that would normally lead to apoptosis.4 This process, 
called carcinogenesis, leads to the acquisition of a set of characteristics, common to most 
cancers, called the hallmarks of cancer.10–12 Carcinogenesis is usually a very slow process 
that can take many years from the first mutation until the formation of the tumor.12,13  
During the early stages of cancer, tumors are typically benign and remain confined 
within the normal boundaries of a tissue. But, as tumors grow and become malignant, they 
gain the ability to break through these boundaries and invade adjacent and/or distant 
tissues – a process called metastasis.14–17  
In primary tumors several subclones coexist, and although some expand, others 
remain dormant or become extinct. Metastases can originate from either a major clone in 
the primary tumor or from minor clones. Metastases can also undergo clonal evolution 
(figure 1).18  
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Figure 1: Clonal evolution in primary tumors and metastases.  
The grey circle represents a normal cell and the central dot depicts the initiating somatic mutation that drives 
the founder clone in the tumor. The different colored circles represent subclones that have accumulated 
successive mutations. Note that in the primary tumor several subclones coexist, and although some expand, 
others remain dormant or become extinct. Metastases can originate from either a major clone in the primary 
tumor (metastasis 1), or from minor clones (metastasis 2). Metastases can also undergo clonal evolution (as 
shown in metastasis 1).18 
Surgical resection and adjuvant therapy can cure well confined primary tumors, 
however, metastatic disease is largely incurable because of its systemic nature and the 
resistance of disseminated tumor cells to existing therapeutic agents. This explains why 
more than 90% of mortality from cancer is attributable to metastases and not the primary 
tumors from which these malignant lesions arise.14–17 
Metastasis is a complex succession of cell-biological events (figure 2) – collectively 
termed the invasion-metastasis cascade – whereby epithelial cells in primary tumors: (1) 
invade locally through surrounding extracellular matrix (ECM) and stromal cell layers, (2) 
intravasate into the lumina of blood vessels, (3) survive the rigors of transport through the 
vasculature, (4) arrest at distant organ sites, (5) extravasate into the parenchyma of distant 
tissues, (6) initially survive in these foreign microenvironments in order to form 
micrometastases, and (7) reinitiate their proliferative programs at metastatic sites, thereby 
generating macroscopic, clinically detectable neoplastic masses.14–17,19 
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Figure 2: The main steps in the formation of a metastasis. 
(a) Cellular transformation and tumor growth. Growth of neoplastic cells is progressive, with nutrients for the 
expanding tumor mass initially supplied by simple diffusion. (b) Extensive vascularization must occur if a 
tumor mass is to exceed the limit of oxygen and nutrients’ diffusion (1–2 mm in diameter). (c) Local invasion 
of the host stroma by some tumor cells occurs by several parallel mechanisms. Thin-walled venules, such as 
lymphatic channels, offer very little resistance to penetration by tumor cells and provide the most common 
route for tumor-cell entry into the circulation. (d) Detachment and embolization of single tumor cells or 
aggregates occurs next, but most circulating tumor cells are rapidly destroyed. The tumor cells that survive 
the circulation become trapped in the capillary beds of distant organs by adhering either to capillary 
endothelial cells or to subendothelial basement membrane that might be exposed. (e) Extravasation occurs 
next – probably by mechanisms similar to those that operate during invasion. (f) Proliferation within the organ 
parenchyma completes the metastatic process. To continue growing, the micrometastasis must develop a 
vascular network and evade destruction by host defenses. Cancer cells can then invade blood vessels, enter 
the circulation and produce additional metastases.14 
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1.1.2. The hallmarks of cancer 
The hallmarks of cancer consist of eight biological capabilities, acquired throughout 
carcinogenesis, that help rationalizing the complexity of cancer. They include sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis, 
reprogramming of energy metabolism and evading immune destruction. Underlying these 
hallmarks are genome instability, which generates the genetic diversity that expedites their 
acquisition, and inflammation, which boosts multiple hallmark functions.10,20 The classical 
representation of the hallmarks of cancer can be seen in figure 3. 
The multistage process of tumor formation is driven by progressive acquisition of 
activating mutations in dominant growth-enhancing genes (oncogenes) and inactivating 
mutations in recessive growth-inhibitory genes (tumor suppressor genes). This means that, 
despite the multitude of genetic and epigenetic alterations found across cancers, a given 
tumor is mostly driven by a select few changes – those that result in the gain of an oncogene 
or the loss of a tumor suppressor gene.1,4,21–23 
Studies by Jain et al.,24 Felsher and Bishop25 and others show that cancer cells are 
often addicted to (i.e., physiologically dependent on) the continued activity of specific 
activated or overexpressed oncogenes for maintenance of their malignant phenotype. 
Indeed, the inactivation of a single critical oncogene can induce cancer cells to differentiate 
into cells with a normal phenotype or to undergo apoptosis. This dependency of tumors 
upon the continued activity of certain oncogenes is called “oncogene addiction”.1,4,13,21,22 
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Figure 3: The hallmarks of cancer and their therapeutic targets. 
Drugs that interfere with each of the acquired capabilities necessary for tumor growth and progression have 
been developed and are in clinical trials or, in some cases, approved for clinical use in treating certain forms 
of human cancer. Additionally, drugs are being developed to target each of the enabling characteristics and 
emerging hallmarks, which also hold promise as cancer therapeutics. The drugs listed are but illustrative 
examples; there is a deep pipeline of candidate drugs with different molecular targets and modes of action 
in development for most of these hallmarks.20 
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1.1.3. Cancer treatment 
According to recent studies, around one in every four deaths in the USA is due to 
cancer.26 And the burden that cancer represents for patients (even for those who survive 
the disease) and their families adds even further relevance to these figures. Therefore, it is 
important to improve current cancer therapies and develop new ones. Currently, the most 
common cancer treatments are surgery, chemotherapy, radiotherapy, immunotherapy and 
targeted therapy.1,27,28 
Surgery consists of the excision of the cancer in its entirety, together with all 
adjacent tissues into which cancer cells may have spreaded. It is the most effective form of 
treatment, but it can only be performed early in the disease and before the cancer spreads 
into tissues that cannot be resected.1 
Chemotherapy and radiotherapy both consist mostly of inducing DNA damage, 
which will cause problems in cell division and bring about apoptosis. The main drawbacks 
of these treatments are that they are not tumor specific, so normal cells that are actively 
proliferating may also be affected (which explains the severe side effects associated with 
these strategies) and also that development of resistance to these therapies is a 
possibility.1,28 
Immunotherapy is a type of cancer treatment designed to boost the body's natural 
defenses to fight cancer.29,30 It has long been recognized that the immune system and 
malignant cells often coexist in a dynamic equilibrium, and the complex interaction 
between growing tumors and the immune system may determine the course of 
disease.20,29,30 Tumors must develop the ability to evade the immune system in order to 
proliferate and metastasize.10,20 The theory of immune surveillance suggests that the 
immune system is proactively able to eliminate abnormal cells and prevent cancer 
formation in the body. Studies have shown that patients with compromised or suppressed 
immune function have an increased risk of developing cancer.31–35 Clearly, the adaptive 
immune response is able to control the growth of some tumors, as evidenced by the 
observation that the presence of tumor-infiltrating lymphocytes (TILs) often is associated 
with improved overall survival (OS), i.e. the percentage of patients that are alive after being 
diagnosed and starting treatment is higher for patients with TILs.36–38 However, the 
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immune system is rendered ineffective as tumors progress. The goal of cancer 
immunotherapy is to boost or restore the ability of the immune system to detect and 
destroy cancer cells by overcoming the mechanisms by which tumors evade and suppress 
the immune response, in essence, to shift the equilibrium back in favor of immune 
protection.34 The traditional approach to immunotherapy has been to increase the 
frequency of tumor-specific T cells through administration of tumor vaccines, cytokines 
such as interleukin-2, and adoptive transfer of TILs.34,39 In the last decade, efforts to 
improve presentation of tumor antigens to the immune system have focused on antigen-
presenting cells such as myeloid dendritic cells. Remarkable achievements in the field have 
already produced a paradigm shift in melanoma treatment: metastatic melanoma, 
previously considered incurable, can now be treated with a potentially curative rather than 
palliative intent.40 This type of treatment has been gaining more relevance in the cancer 
research field in recent years and, in 2013, it was considered the breakthrough of the year 
by science magazine.41 
Targeted therapy refers to a new generation of anti-cancer drugs (small-molecule 
inhibitors and monoclonal antibodies) designed to interfere with a specific molecular target 
(typically a protein) that is believed to have a critical role in tumor growth or 
progression.20,42–44 The introduction of mechanism-based targeted therapies to treat 
human cancers has been considered as one of the fruits of decades of remarkable progress 
of research into the biology of cancer pathogenesis.20 Targeted therapeutics can be 
categorized according to their respective effects on one or more hallmark capabilities,10,20 
as illustrated in the examples presented in figure 3. Most of the hallmark-targeting cancer 
drugs developed to date have been deliberately directed toward specific molecular targets 
that are involved in one way or another in enabling particular capabilities.20 Such specificity 
of action has been considered a virtue, as it presents inhibitory activity against a target 
while having, in principle, relatively fewer off-target effects and thus less nonspecific 
toxicity.20 However, despite continuous breakthroughs in cancer therapy and drug 
development, targeted therapy is almost inevitably challenged by the occurrence of drug 
resistance, mainly due to tumor heterogeneity (i.e., the existence of tumor subpopulations 
harboring distinct mutations – some of which resistant to the drug), therefore allowing 
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cancer progression.20,45,46 More recently, with the concept of synthetic lethality (two genes 
are synthetic lethal if a mutation of either alone is compatible with viability but mutation 
of both leads to death)47 and the increasing knowledge about cancer pathways a new era 
in cancer therapy has emerged. The old concept that one single drug would treat cancer is 
now outdated; nowadays, most studies focus in finding two (or more) drugs whose 
combination increases tumor killing and reduces resistance.48–50 The most common 
approach to find synthetically lethal interactions are loss of function genetic screens, which 
have rendered several combinations that were proven to have a major clinical impact.51,52 
One successful example was the discovery that resistance to BRAF inhibition in BRAFV600E 
mutant colon cancer can be overcomed by co-targeting EGFR (which resulted in three 
clinical trials).48 Another appealing example of the concept of synthetic lethality is the 
discovery of toxicity of Poly (ADP-ribose) polymerase (PARP) 1 and 2 inhibitors in BRCA1 
and BRCA2 mutant cells, which has already been clinically validated in breast cancer.53,54 
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1.2. Hypoxia, angiogenesis and antiangiogenic therapy 
1.2.1. Hypoxia and angiogenesis 
Oxygen and nutrients are essential for the life of every cell in the body. Therefore, 
the establishment of a functional, integrated vascular system is crucial for tissue growth 
and homeostasis.55,56 Similarly, tumor development and progression is dependent on 
angiogenesis, as the recruitment of new blood vessels to the tumor site is required for the 
delivery of nutrients and oxygen and for the removal of waste products.57 In fact, for 
tumors to growth beyond the size of about 1-2 mm3 they must switch to an angiogenic 
phenotype.58,59 
The angiogenic process starts when cancer cells experience hypoxia and mount 
adaptive responses to deal it.55 The term hypoxia refers to a condition characterized by a 
cellular or tissue level of oxygenation lower than normal (in the context of tumors, as 
having an internal partial pressure of oxygen of less than 10–15mmHg (≈3%)).60 In most 
solid tumors, hypoxic areas are frequent events, due to: (a) structural and functional 
abnormalities of the tumor micro-vessels, (b) an increase in diffusion distances, given the 
highly proliferative capacity of tumor cells, and (c) tumor-associated anemia leading to a 
reduced oxygen transport capacity of the blood.61  
The hypoxia inducible factor (HIF) family of transcription factors has emerged as the 
master regulator of oxygen tension homeostasis and controls fundamental 
pathophysiological pathways (figure 4).62–64 HIF-1 is a heterodimeric protein comprising a 
constitutively expressed α and β subunits, which is tightly regulated by oxygen 
availability.65,66 Under normoxic conditions, HIF-1α is hydroxylated by oxygen-dependent 
prolyl hydroxylase domain proteins (PHDs), and rapidly targeted for ubiquitination and 
proteasomal degradation. Furthermore, under normoxic conditions, HIF-1α is hydroxylated 
at residue Asn803 by factor inhibiting HIF-1 (FIH), which inhibits the recruitment of the Cbp-
p300 cofactor and blocks HIF-1-dependent transcriptional activation.65,66 
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Figure 4: Regulation of HIF-1α and HIF-1α-dependent gene expression. 
Under normoxic conditions, HIF-1α is continuously transcribed and translated, but it is rapidly degraded 
through the pVHL pathway following hydroxylation of Pro402 and Pro564 by PHDs. FIH mediates the 
hydroxylation of Asn803, which inhibits the recruitment of co-factors for transcription. When the oxygen 
tension decreases, HIF-1α is stabilized, translocates to the nucleus and dimerises with HIF-1β—enabling 
transcription of a large number of genes involved in cancer biology. RTKs boost translation of HIF-1α via 
activation of the mTOR pathway.64 
Contrarily, in hypoxia, due to the lack of substrate, PHDs become less active and this 
leads to the HIF-1α stabilization, nuclear translocation and dimerization with HIF-1β.65,66 By 
binding to hypoxia responsive elements (HRE) located in the promotor region of several 
genes, heterodimeric HIF-1 activates the transcription of its numerous targets involved in 
cellular adaptation to hypoxia, including angiogenesis, metabolism, proliferation, 
metastasis and differentiation, all together contributing to tumorigenesis.60,62–64,67 
In hypoxic conditions, HIF gets activated and upregulates the expression of several 
genes. Some of these are responsible for the production of proangiogenic factors, such as 
VEGF, which activates endothelial cells (ECs) and promote angiogenesis.64,67,68 ECs at the 
leading edge of the vascular sprout extend filopodia and migrate toward angiogenic signals. 
VEGF activates VEGFR2 to stimulate tip cell migration. Tip cell migration requires basement 
membrane degradation (in part due to MMP), EC junction loosening (caused by VE-
cadherin, ZO-1, and others), and pericyte detachment (regulated by Ang2).68 VEGF 
increases the permeability of the vessel, allowing the extravasation of plasma proteins 
(e.g., fibronectin and fibrinogen) that are deposited as a provisional matrix layer while the 
preexisting interstitial matrix is remodeled by proteases. Tip cells adhere to the ECM, 
mediated by integrins, and migrate toward guidance signal molecules (e.g., semaphorins 
and ephrins). Stalk cells trail behind the tip cell and proliferate to allow sprout elongation 
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and lumen formation. This system allows vascular migration (by tip cells) and elongation of 
the shaft (by proliferating stalk cells).68 When two tip cells meet, they fuse and a connected 
lumen is formed to allow blood flow through the new vessel. This perfuses the hypoxic 
tissue, and the resultant oxygen and nutrient delivery leads to decreased levels of 
angiogenic signals, inactivation of EC oxygen sensors, and increased proquiescent 
molecules that lead to EC quiescence.68 
Hypoxia is responsible for many effects in tumor biology: selection of genotypes 
favoring survival under hypoxia reoxygenation injury (such as TP53 mutations),69 
prosurvival changes in gene expression that suppress apoptosis70 and support autophagy71 
and the anabolic switch in central metabolism.72 Hypoxia also enhances receptor tyrosine 
kinase mediated signaling,73 tumor angiogenesis,74 vasculogenesis,75 the epithelial-to-
mesenchymal transition,76 invasiveness77 and metastasis,78 as well as suppressing immune 
reactivity.79 In addition, it also contributes to loss of genomic stability through the 
increased generation of reactive oxygen species (ROS)80 and the downregulation of DNA 
repair pathways,62 as well as contributing to resistance to radiotherapy and 
chemotherapy.64 
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1.2.2. Antiangiogenic therapy 
Antiangiogenic (AA) therapy stems from the fundamental concept that tumor 
growth, invasion, and metastasis are angiogenesis-dependent.59,81 The microvascular ECs 
recruited by tumors (to form new blood vessels) have become an important target in 
cancer therapy because, unlike cancer cells (the primary target of cytotoxic chemotherapy), 
that are genetically unstable with unpredictable mutations, the genetic stability of ECs 
makes them less susceptible to acquired drug resistance.81 Also, since VEGF is mainly 
produced by tumor cells promoting angiogenesis, a low side toxicity is expected from this 
therapy. Therefore, targeting tumor vasculature has arisen as an appealing anti-cancer 
therapeutic approach.55,57,82 
To date, ten drugs that target VEGF or its receptors have been approved for the 
treatment of various malignant diseases83 – see table 1.  
Table 1: Currently antiangiogenic drugs approved for cancer treatment – adapted from Jain K. Rakesh.83  
Drug Approved Indication 
Bevacizumab 
- metastatic colorectal cancer (with chemotherapy) 
- metastatic nonsquamous NSCLC (with chemotherapy) 
- metastatic breast cancer (with chemotherapy) 
- metastatic renal cell carcinoma (RCC) (with IFN-α) 
- advanced cervical cancer (with chemotherapy) 
Sunitinib 
- metastatic RCC 
- gastrointestinal stromal tumor 
- primitive neuroectodermal tumor 
Sorafenib 
- metastatic RCC 
- unresectable hepatocellular carcinoma 
Pazopanib 
- metastatic RCC 
- advanced soft tissue sarcoma 
Vandetanib - advanced medullary thyroid cancer 
Axitinib - advanced RCC 
Regorafenib - chemorefractory metastatic colorectal cancer 
Aflibercept - chemorefractory metastatic colorectal cancer 
Cabozantinib - advanced medullary thyroid cancer 
Ramucirumab 
- metastatic gastric and GEJ cancers 
- metastatic GEJ cancers (with chemotherapy) 
- metastatic NSCLC (with chemotherapy) 
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Antiangiogenic therapies have been widely used in clinical trials, with delayed tumor 
progression in some patients, leading to improved progression-free survival and overall 
survival compared with standard therapy. But unfortunately, a significant number of 
patients either do not respond to AA therapy or rapidly develop resistance to it.55,64 
The functional consequences of AA therapies on the tumor microenvironment are 
poorly understood and a matter of debate; at least two contrasting hypotheses have been 
proposed: (1) AA therapy causes vascular “regression” that results in increased intratumor 
hypoxia, selection of metastatic clones and resistance to therapy and (2) AA therapy 
“normalizes” the vasculature, with a consequent decrease in intratumor hypoxia and 
interstitial pressure, which is associated with improved delivery of chemotherapy.64,83 
These two hypotheses are not necessarily mutually exclusive, but might be cancer and 
genotype-dependent.64  
The first hypothesis, is one of the explanations for cancers’ (intrinsic or acquired) 
resistance to AA therapies and the second explains why AA therapies show clinical benefits 
for a short period of time (in combination with chemotherapy), i.e., AA agents are believed 
to transiently ‘‘normalize’’ the abnormal tumor vasculature, resulting in improved blood 
perfusion. The latter would decrease hypoxia (known to confer resistance to radio-, chemo- 
and immune therapies) and increase drug accessibility. Therefore, therapies given during 
the window of normalization might achieve greater efficacy. The normalized vessels would 
also resist intravasation of cancer cells from the primary tumor to the blood stream, 
potentially decreasing metastases.83–85  
Several mechanisms of resistance to AA therapy have been proposed, however, 
they all stem from the fundamental concept that vessel regression increases tumor 
hypoxia.86,87 The most common escape mechanism is the upregulation of alternative 
proangiogenic signals (such as FGF, PDGFs and PlGF),88,89 the use of different modes of 
vascularization (vessel cooption (by growing around preexisting vessels), vascular mimicry 
(replacement of ECs by tumor cells), and vasculogenesis (vessel growth from bone marrow–
derived progenitor cells))68,90,91 increasing pericyte coverage of the vasculature92 and/or 
activating an invasive phenotype.93–96 Hypoxic responses have a role in many adaptive 
mechanisms, as described in the last paragraph of section 1.2.1.. 
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1.3. Colorectal Cancer 
1.3.1. Facts & figures 
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the 
second leading cause of cancer death in both men and women in the United States.97 In 
Europe, CRC represents the second most common cancer and leading cause of cancer 
death, in both genders combined.98 Although there is an increasingly well-described 
genetic component (accounting for about 5% of disease burden), the dominant causative 
factors are environmental.99,100 CRC is therefore a major global health problem that the 
scientific community must address seriously in order to find new and better solutions.  
CRC usually develops slowly, over a period of 10 to 20 years.101 Most begin as a 
noncancerous growth, called a polyp, developing on the inner lining of the colon or rectum. 
The most common kind of polyp is called an adenomatous polyp or adenoma. Although all 
adenomas have the capacity to become cancerous, less than 10% are estimated to progress 
to invasive cancer.102,103 Cancers that develop in glandular cells are called adenocarcinoma, 
and account for most CRC (approximately 96%).104 The initial step in CRC tumorigenesis is 
the adenoma formation, associated with loss of APC. Larger adenomas and early 
carcinomas then acquire mutations in the small GTPase KRAS (which causes proliferative 
signaling to be continuously active), followed by loss of chromosome 18q and mutations in 
TP53.105  
Given the recognized transition from premalignant adenomas to invasive 
carcinomas106 this type of cancer has, in principle,  a great potential to be detected in early 
stages, increasing the likelihood of cure. Yet, because CRC’s main detection method 
(colonoscopy) is quite invasive, most people avoid it until it’s too late (i.e., when the cancer 
has already metastasized). The majority of patients with metastatic CRC (mCRC) cannot be 
cured and therefore, metastasis remains the major cause of cancer-related death107. Yet, 
over the past years, the outcome of these patients has been improved, mainly due to the 
introduction of targeted therapies in the clinic.108,109 
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1.3.2. Targeted therapy in CRC 
Considerable progress has been made in the treatment of colorectal cancer from 
the era when 5-fluorouracil (chemotherapeutic drug) was the only effective agent for this 
disease.109 In addition to new chemotherapeutic agents, such as oxaliplatin, irinotecan, and 
capecitabine, the advent of targeted therapies has contributed considerably to the 
treatment of colon cancer and has improved clinical outcomes. An increased understanding 
of cancer at the molecular and genetic level has allowed for the development of 
therapeutics that target the multiple pathways essential to malignant behavior.45,109 
While currently approved targeted therapies in advanced colorectal cancer (table 
2) is limited to monoclonal antibodies against VEGF and EGFR, many more drugs targeting 
different pathways of oncogenesis are in development.109 
Sustained angiogenesis is one of the hallmarks of cancer.10,20 One mechanism 
responsible for the induction of angiogenesis is altered gene transcription, resulting in 
overproduction of VEGF at the tissue level.110 Both the ligand (VEGF) and its receptors 
(VEGFR) are known to be overexpressed in colon cancer, and their presence indicates a 
poor prognosis.111–113 There is also evidence that VEGF inhibition can have direct antitumor 
effects through a separate mechanism apart from angiogenesis.114,115 Based on these 
observations, there is a great rationale for targeting the VEGF pathway in CRC. However, 
patients either do not respond to the treatment or those who respond eventually develop 
resistance – the mechanisms have already been described in the last paragraph of section 
1.2.2.. 
Table 2: Currently FDA approved targeted therapies for colorectal cancer – adapted from FDA.116 
Drug Target 
Bevacizumab anti-VEGF 
Zaltrap anti-VEGF-A and anti-PlGF 
Cetuximab anti-EFGR 
Panitumumab anti-EGFR 
Regorafenib multi-kinase inhibitor 
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Figure 5: The epidermal growth factor receptor signaling pathway. 
Activation of membrane kinases including EGFR by external growth factors initiates receptor dimerization 
and subsequent activation of the intracellular kinase domain, which in turn leads to the activation of 
intracellular pathways. Through the small adaptor proteins Sos and Grb, the KRAS signalling cascade is 
activated, leading to increased proliferation. Part of the KRAS pathway is BRAF, which explains why non-
constitutively activated KRAS and BRAF are necessary for EGFR blockade to work.105 
Unchecked and deregulated growth are also hallmarks of cancer.10,20 Among the 
growth factors implicated in the development of colon cancer, EGF and its receptors have 
been studied the most. EGFR is a member of the ErbB family of receptors, a group that is 
abnormally activated in many epithelial malignancies, such as CRC.117 It has been 
demonstrated that potentially 80% of colon cancers exploit EGFR for their 
pathogenesis.118,119 There is also evidence to suggest that EGFR inhibition functions not 
only through downregulation of growth signals, but also through downregulation of 
proangiogenic factors including VEGF and IL-8, leading to a decrease in tumor microvessel 
density.120 Further supporting the AA effect of EGFR inhibition is the fact that EGFR resistant 
tumors demonstrate upregulation of VEGF.121 Based on these observations, there is also a 
great rationale for targeting the EGFR pathway (figure 5) in CRC. 
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Investigations into the molecular basis of response to EGFR-blocking antibodies 
started in 2005 and since then a rapidly accumulating body of knowledge has indicated that 
resistance to EGFR blockade in mCRC is related to constitutive activation of signaling 
pathways downstream of EGFR.100  
Mutations in KRAS were the first to be causally implicated in resistance to EGFR-
targeted monoclonal antibodies, leading to the exclusion of patients with chemorefractory 
mCRC with tumors bearing KRAS mutations from treatment with single-agent cetuximab or 
panitumumab.122,123 Also, because not all KRAS wild-type patients benefit from treatment 
with EGFR-directed therapy, research has flourished to identify additional biomarkers of 
resistance that could account for the heterogeneity in clinical response.100  
Several studies based on preclinical models and tumor samples obtained at relapse 
identified molecular mechanisms that lead to acquired resistance to EGFR blockade in 
colorectal cancer: (1) mutations in the EGFR extracellular domain124 (which impairs the 
binding of the antibody to the receptor); (2) amplification of RTKs125–127 (such as ERBB2 or 
MET); (3) mutations in RAS and RAF genes (both point mutations and gene 
amplification).128–130 
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1.3.3. Combination of anti-EGFR with anti-VEGF therapies in CRC 
Multiple cellular pathways influence the growth and metastatic potential of tumors. 
This creates heterogeneity, redundancy, and the potential for tumors to bypass signaling 
pathway blockade, resulting in primary or acquired resistance.131,132 A multifaceted 
approach, involving targeted inhibition of multiple signaling pathways, may be more 
effective than inhibition of a single target and may help overcome tumor resistance by 
blocking potential “escape routes”.131 
Two key elements in the growth and dissemination of tumors are the epidermal 
growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF). Close 
relationships between these factors exist: VEGF signaling is up-regulated by EGFR 
expression and, conversely, VEGF up-regulation (independent of EGFR signaling) seems to 
contribute to resistance to EGFR inhibition, however, the mechanism behind this is not well 
known yet.133–137 
Both EGFR and VEGF are overexpressed in patients with colorectal 
cancer112,113,138,139 and several studies have showed that drugs targeting either the EGFR or 
the VEGF pathways have clinical benefit in several human cancers, either alone or in 
combination with standard cytotoxic therapies.131 Therefore, it is expected that the 
inhibition of both these pathways could improve antitumor efficacy and overcome 
resistance. 
Anti-VEGF treatment used in conjunction with EGFR inhibitors has shown promising 
results in preclinical and clinical studies. A xenograft study blocking VEGF (with VEGF 
antisense oligonucleotide) and EGFR (with C225 antibody) demonstrated synergistic 
antitumor activity,140 and mice intraperitoneally injected with human colon cancer cells 
showed improved antitumor activity in response to anti-EGFR antibody (C225) and an anti-
VEGFR2 antibody (DC101).141 Phase I and II clinical studies in mCRC indicate increased 
efficacy with the combination of anti-VEGF and anti-EGFR therapy, with improved response 
rate, increased time to progression, and increased overall survival in patients who received 
cetuximab and bevacizumab142 versus historical control groups of patients who received 
cetuximab,143 bevacizumab monotherapy,144 or cetuximab plus chemotherapy.145 This 
activity of the combination of cetuximab and bevacizumab may be due to the fact that 
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resistance to EGFR inhibitors is mediated, at least partly, by activating VEGF-dependent 
signaling.146,147 
However, two other clinical studies combining chemotherapy, anti-EGFR and anti-
VEGF blocking antibodies (CAIRO2 and PACCE) showed disappointing results (figure 6): a 
significant decrease in progression free survival (i.e., the period of time after the start of  
treatment of a disease that patients live with stable disease, without it getting worse) and 
a poorer quality of life, due to the secondary effects of the drug combination.143,148 The 
negative results of the CAIRO2 trial might be explained by a negative interaction between 
cetuximab and bevacizumab. This negative interaction is caused by hypertension, a 
common side effect of bevacizumab treatment, that was recently shown to correlate with 
clinical outcome in patients with colorectal cancer.149 In the study it was observed that 
hypertension was less frequent in the group treated with chemotherapy plus cetuximab 
and bevacizumab, in opposition to the group treated with only chemotherapy plus 
bevacizumab, which suggests a decreased efficacy of bevacizumab when administered in 
combination with cetuximab.150 Also, as expected, the KRAS genotype affects the response 
to anti-EGFR treatment: patients with WT-KRAS tumors have longer progression-free 
survival than those with mutated-KRAS tumors.150 However, no clear mechanism explaining 
the failure of this combination has been found so far, making it an attractive research topic. 
 
Figure 6: Progression-free survival in the CAIRO II clinical trial. 
In this randomized trial in patients with metastatic colorectal cancer, the addition of cetuximab to treatment 
with capecitabine, oxaliplatin, and bevacizumab resulted in a significant decrease in progression-free survival 
and a poorer quality of life. The KRAS genotype affects the response to anti-EGFR treatment: patients with 
wild-type KRAS tumors have longer progression-free survival than those with mutated-KRAS tumors.150 (CB = 
chemotherapy + bevacizumab; CBC = chemotherapy + bevacizumab + cetuximab)  
20 
 
1.4. Objectives 
Tumor hypoxia, a common feature in most cancers, is further aggravated upon 
antiangiogenic treatment and, while it can represent a lethal stress to some tumor cells, it 
can also function as a potent driving force of malignancy and drug resistance for others.86,87  
A critical step to increase the efficacy of AA therapies and develop new cancer 
fighting strategies it is to overcome their main cause of resistance – hypoxia. Also, to date, 
no clear prognostic or predictive markers of response to AA agents have been found, which 
makes the search for biomarkers to identify patients who may benefit from angiogenesis 
inhibitors (and also serve as potential drug targets) another critical step to upgrade the 
efficacy of AA therapies. 
This project aims to improve the efficacy of AA agents using an in vitro translational 
approach. In a first part, we intend to find the mechanism(s) underlying the resistance to 
the combination of bevacizumab and cetuximab showed in the CAIRO2 clinical trial. To that 
aim, cells were treated with cetuximab, both in normoxia and in hypoxia, to mimic EGFR 
inhibition in combination with anti-VEGF. Then, using functional (such as colony formation 
assays) and molecular (e.g. western blotting) assays we tried to uncover the mechanism(s) 
that confer resistance to the anti-EGFR treatments in hypoxia. In a second part, using the 
concept of synthetic lethality, we aim to identify novel and powerful synthetic lethal 
interactions with hypoxia. To do that, we analyzed gene expression of six different CRC cell 
lines cultured in both normoxia and hypoxia so as to derive a CRC specific hypoxia-
signature. We performed a functional genetic screen (using a collection of RNA interference 
vectors that target the genes of the hypoxia-signature) to identify which of these genes are 
pivotal for the survival of CRC cells cultivated under hypoxic conditions.  
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2. Results and Discussion 
2.1. Resistance to anti-EGFR treatments in hypoxia in WT4 CRC cells 
In the first part of this project, we used an in vitro approach to study how CRC cell 
lines respond to the combination of EGFR and VEGF inhibition. EGFR was inhibited by the 
monoclonal antibody cetuximab, given its approval for the treatment of CRC patients in the 
clinic. To mimic the effect of anti-VEGF therapy (which primarily targets tumor ECs of the 
blood vasculature and therefore cannot be used in an in vitro experimental setting) we 
cultured cells in a hypoxic environment (1% O2). The efficacy of this treatment was 
determined in a panel of CRC cell lines using a long term proliferation assay (10-15 days). 
Our data shows that despite substantial sensitivity to cetuximab treatment in 
normoxia (21% O2), quadruple WT (WT4 – WT for KRAS, NRAS, BRAF and PIK3CA) CRC cell 
lines (DiFi, Lim 1215, CCK81 and OXCO2) become more resistant to EGFR inhibition when 
cultured in hypoxia (1% O2, Figure 7A). We were able to recapitulate this finding using 
gefitinib and neratinib, two TKIs that inhibit EGFR and EGFR/HER2, respectively (Figure 7B). 
This hypoxia-dependent phenotype seems to be specific for WT4 CRC cell lines, as 
proliferation of KRASMUT (LoVo) or BRAFMUT (HT-29) CRC cell lines was not significantly 
affected by EGFR inhibition at any of the studied oxygen tensions (Figure 7C). This result 
was not surprising, especially for the KRASMUT context, since patients with KRAS mutations 
respond poorly to cetuximab, which lead to their exclusion from treatment with the EGFR 
inhibitor by FDA.151 Of note, all tested cell lines were able to survive for over 15 days at 1% 
O2, only displaying a slight impairment in proliferation when compared to 21% O2 
conditions. In addition, these results mirror the clinical trial CAIRO2, where KRAS WT 
patients did not benefit from the combination of cetuximab and bevacizumab151. Therefore 
this system is of potential interest to study the mechanisms of resistance to EGFR inhibition 
in hypoxia and, possibly, get some molecular insight to explain and overcome the CAIRO2 
disappointing results.  
To validate these findings we tested lysates of drug/hypoxia-treated cells with 
phosphoprotein-specific antibodies that identify the activated state of components of the 
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Figure 7: Hypoxia induces resistance to EGFR inhibition in WT4 CRC cell lines. 
Long-term colony formation assay of a CRC cell line panel consisting of WT4 (DiFi, Lim, CCK81 and OXCO2), 
KRASMUT (LoVo) and BRAFMUT (HT-29) cell lines. Cells were treated with increasing concentrations of 
cetuximab (A and C) and gefitinib or neratinib (B) and incubated at 21% or 1% O2 for 10-15 days. For each cell 
line, all plates were seeded, fixed, stained and scanned at the same time.  
survival, proliferation, apoptosis, hypoxia and EGFR signalling pathways (Figure 8). As 
expected, cetuximab treatment resulted in a decrease in Tyr 1068 phosphorylation of EGFR, 
which reflects its inhibition. Moreover, CRC cells accumulated the HIF1α transcription 
factor when cultured in hypoxia, confirming that the hypoxic sensing machinery was active 
in our experimental setting. Of note, cetuximab decreased HIF1α accumulation in hypoxia, 
which is concordant with published data, where the use of EGFR inhibitors has been shown 
to decrease tumor cell expression of HIF-1α and VEGF.152,153 We also observed that 
cetuximab-treated cells cultured in hypoxia have more phosphorylated AKT, a known 
marker of survival,154 which confirms biochemically the resistance phenotype observed in 
the long term colony formation assay. In light with these findings, blockage of apoptosis in 
cetuximab-treated cells in hypoxia is confirmed by the low levels of cleaved PARP 
(apoptosis marker),155 indicating that these cells are indeed protected against apoptotic 
cell death. Phosphorylated ERK is also higher in hypoxia-treated DiFi cells, yet this is not so 
clear in the other cell lines, which might have to do with the time point when samples were 
taken for analysis; a time course experiment would elucidate further. Overall, with this 
experiment we were able to biochemically confirm the long term proliferation assay 
resistant phenotype.  
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Figure 8: Hypoxia induced resistance to cetuximab in WT4 CRC cell lines confirmed by Western blot. 
Biochemical responses of DiFi, Lim 1215, OXCO2 and CCK81 cells to cetuximab, hypoxia, or their combination, 
were documented by western blot analysis. Cells were harvested at 24 hours (Lim 1215, OXCO2 and CCK81) 
or 48 hours (DiFi) after cetuximab treatment (DiFi cells were treated with 1 μg/mL of cetuximab and Lim 1215, 
OXCO2 and CCK81 cells were treated with 5 μg/mL of cetuximab). Treatment with cetuximab resulted in a 
decrease of EGFR (and consequently pEGFR) as expected; in hypoxia, cells treated with cetuximab exhibit a 
higher phosphorylation of AKT and ERK as compared with normoxia-treated cells and as a consequence, 
normoxia-treated cells express more cleaved PARP than hypoxia-treated cells. HIF1α served as a control for 
the hypoxia treatment and tubulin served as a loading control. 
HIF is the master regulator of the cellular adaptations to hypoxia. Given that the 
resistance to EGFR inhibition in the cell lines used in our study only occurs in hypoxia we 
investigated whether HIF was mediating the resistance phenotype. We addressed this 
question by performing gain and loss of function experiments, where we treated cells with 
gefitinib or neratinib in combination with DMOG (HIF stabilizer) or digoxin (HIF inhibitor). 
We observed that treatment with DMOG (dimethyloxalylglycine, a HIF stabilizer agent by 
inhibition of PHDs) did not confer resistance to EGFR inhibition in normoxia (Figure 9A) and 
that treatment with digoxin did not sensitize cells to EGFR inhibition in hypoxia (Figure 9B). 
These results indicate that HIF is not mediating the resistance to EGFR inhibition in hypoxia. 
These findings are concordant to our previous biochemical analysis where upon cetuximab 
treatment in hypoxia HIF accumulation was reduced comparing to the untreated cells. 
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Figure 9: HIF is not mediating the resistance to EGFR inhibition in hypoxia. 
A, Response of Lim cells to the combination of EGFR inhibitors gefitinib or neratinib and DMOG. Lim cells 
were cultured with increasing concentrations of EGFR inhibitor gefitinib or neratinib alone, DMOG alone, and 
their combination. Cells were incubated at 21% for 10 days. B, Response of Lim cells to the combination of 
gefitinib and digoxin. Lim cells were cultured with increasing concentrations of gefitinib alone, digoxin alone, 
and their combination. Cells were incubated at 21% or 1% O2 for 10 days. All plates were seeded, fixed, 
stained and scanned at the same time. 
This result increases the novelty potential of this project, given that most described 
resistance mechanisms in hypoxia are HIF-dependent.156,157  
Amplification of the MET receptor is a known driver of resistance to anti-EGFR 
therapies in CRC158 and although it has also been reported as a hypoxic (HIF1) target 
gene,159 both features were never assessed together in the context of CRC. To test if MET 
was implicated in the resistance to EGFR inhibition in hypoxia we treated Lim 1215 cells 
with EGFR inhibitors (gefitinib or neratinib) in a combinatory matrix with increased 
concentrations of the MET inhibitor crizotinib in both normoxia and hypoxia (Figure 10A). 
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Figure 10: MET is not implicated in the resistance to EGFR inhibition in hypoxia. 
A, MET inhibition does not sensitize Lim 1215 cells to EGFR inhibition in hypoxia. Lim 1215 cells were cultured 
with increasing concentrations of EGFR inhibitor gefitinib alone, MET inhibitor crizotinib alone, and their 
combination. Cells were incubated at 21% or 1% O2 for 10 days. All plates were seeded, fixed, stained and 
scanned at the same time. B,  Hypoxia and cetuximab downregulate MET phosphorylation. Biochemical 
responses of DiFi cells to cetuximab, hypoxia, or their combination, were documented by western blot 
analysis. Cells were harvested at 6, 24 and 48 hours after cetuximab treatment (1 μg/mL). Treatment with 
cetuximab resulted in downregulation of pMET. Hypoxia also results in pMET downregulation. 
Cells were relatively insensitive to crizotinib and no synergistic activity was observed 
between EGFR and MET inhibition, with cells still exhibiting resistance to EGFR inhibition in 
hypoxia compared to normoxia. This result was confirmed by western blot where we 
observed that combination of hypoxia and cetuximab actually downregulated MET 
phosphorylation (Figure 10B), and thus excludes a role of MET in the resistance to EGFR 
inhibition in hypoxia.  
Upregulation of RTKs is one of the most common mechanisms of acquired 
resistance to targeted cancer therapies,160 therefore to address if any RTK upregulation was 
causing resistance to EGFR inhibition in WT4 CRC cell lines in hypoxia we performed a 
Phospho-RTK array in Lim 1215 cells (Figure 11). In this experiment, cetuximab treatment 
efficiently reduced phosphorylated EGFR levels. We observed an upregulation of 
phosphorylated HER3, INSR and IGF1R in cetuximab-treated cells, although INSR and IGF1R 
phosphorylation was higher in normoxia. Unexpectedly there was not any upregulated RTK 
exclusively in hypoxia-treated cells, therefore excluding RTK upregulation (at least those 
RTKs present in this assay) as the cause of resistance to EGFR inhibition in WT4 CRC cell 
lines in hypoxia. HER3 is a member of the Erbb family and upon 
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Figure 11: RTK upregulation excluded as the cause of resistance to EGFR inhibition in WT4 CRC cell lines in 
hypoxia. 
RTK phosphorilation in Lim 1215 cells was analysed using a phospho-RTK array. Cells were harvested 48 hours 
after cetuximab treatment. Treatment with cetuximab resulted in upregulation of HER3, INSR and IGF1R in 
Lim 1215 cels. 
EGFR inhibition its phosphorylation is increased; HER3 phosphorylation acts as a 
compensatory mechanism to EGFR phospho-downregulation.161 We hypothesize that INSR 
and IGF-1R, two important membrane receptors involved in glucose metabolism, are 
upregulated by cells as an attempt to cope with the toxicity of the EGFR inhibition in 
normoxia. It has been shown that CRC cells with hyper-activated IGF-1R pathway can 
escape anti-EGFR mediated cell death through continued activation of the PI3K pathway,162 
however, in the tested cell lines this was not sufficient and cells eventually die. In hypoxia, 
as cells are able to cope better with EGFR inhibition, INSR and IGF1R rescue mechanism 
seems to be less required. 
Development of mutations in the RAS/RAF signaling pathway is a mechanism of 
resistance to anti-EGFR therapies in CRC. Mutations in the RAS/RAF oncogenes have been 
found in CRC patients who become resistant to cetuximab treatment, however, it is not 
completely clear if these mutations developed during cetuximab treatment or if they were 
already preexistent, but in a very low number to be detected.122 To test if our cells 
developed mutations in the oncogenes KRAS, BRAF or NRAS after treatment with EGFR 
inhibitors in hypoxia, we sequenced DiFi and Lim 1215 cells after two weeks of treatment 
(with and without cetuximab at 21% or 1% O2), when the resistance phenotype was noted. 
No KRAS, BRAF or NRAS hot spot mutations were found in these cells lines in the tested 
conditions, which also excluded this hypothesis as the cause of resistance.  
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Another possible mechanism to explain the resistance to EGFR inhibition in WT4 
CRC cells is the activation of RAS by hypoxia, since it has been shown that KRASWT CRC cells 
cultured in hypoxia have higher levels of activated RAS than in normoxia.163 To test this 
hypothesis, we measured the amount of active RAS by performing a GTP-RAS pull-down 
followed by western blot analysis (Figure 12). We observed that, indeed, DiFi cells have 
higher active RAS levels when cultured in hypoxia. Strikingly, upon cetuximab treatment, 
cells cultured in normoxia barely have active Ras while hypoxia cells maintain higher levels 
of active Ras. This feature explains why WT4 CRC cells display higher levels of pAKT and 
pERK and reduced levels of cleaved PARP when treated with cetuximab in hypoxia. 
 
Figure 12: Hypoxia activates RAS, which promotes cell proliferation and protects cells from apoptosis. 
Biochemical responses of DiFi cells to cetuximab, hypoxia, or their combination, were documented by 
western blot analysis. DiFi cells were harvested at 48 hours after cetuximab treatment (1 μg/mL). A GTP-RAS 
pull-down was performed with part of the lysates. Treatment with cetuximab resulted in a decrease of EGFR 
(and consequently pEGFR) as expected; GTP-RAS is higher in hypoxia, both in the cetuximab treated and 
untreated cells. In hypoxia, cells treated with cetuximab exhibit a higher phosphorylation of AKT and ERK as 
compared with normoxia-treated cells. Treated cells express more cleaved PARP in normoxia than in hypoxia. 
HIF1α served as a control for the hypoxia treatment and HSP90 served as a loading control. 
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To test if WT4 CRC cells are dependent on the PI3K pathway for their survival upon 
EGFR inhibition in hypoxia, we blocked EGFR together with PI3K pathway. To do that we 
performed a loss of function experiment, where we blocked the PI3K pathway using the 
AKT inhibitor MK2066 (Figure 13A). Lim 1215 cells treated with MK2066 still exhibited 
resistance to EGFR inhibition in hypoxia, however, since the activity of the drug was not 
confirmed by western blot, and given the lack of cell killing by this inhibitor in the range of 
concentrations used no definitive conclusions can be made at this point. Therefore, we 
performed the same loss of function experiment but using a PI3K inhibitor (GDC0441) 
(Figure 13B). Cells treated with GDC0441 also still exhibited resistance to EGFR inhibition 
in hypoxia, indicating that the PI3K/AKT signaling pathway is not essential for the survival 
of these cells to EGFR inhibition in hypoxia, as the resistance phenotype was not reversed 
with the combination. The blockage of PI3K-AKT signaling with GDC0441 in this experiment 
seems more efficient than with MK2066, since it killed cells at higher concentrations in both 
oxygen tensions. 
 
Figure 13: EGFR and PI3K inhibition does not intercept resistance to EGFR inhibition in hypoxia in WT4 CRC. 
Lim 1215 cells were cultured with increasing concentrations of EGFR inhibitor gefitinib alone, PI3K inhibitor 
GDC0441 or AKT inhibitor MK2066 alone, and their combinations. Cells were incubated at 21% or 1% O2 for 
10 days. All plates were seeded, fixed, stained and scanned at the same time. 
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We also tested the dependency of our cells on the MAPK pathway for their survival 
upon EGFR inhibition in hypoxia. It has been previously shown that the combination of 
EGFR and MEK inhibition can intercept the acquisition of resistance to anti-EGFR therapies 
in CRC,129 yet never in the context of hypoxia or in combination with AA agents. We tested 
this hypothesis by performing a loss of function experiment, where we blocked the MAPK 
pathway using MEK inhibitors Selumetinib or Trametinib in Lim 1215 cells (Figure 14). We 
observed that MEK inhibition is highly effective in killing Lim 1215 cells in normoxia and 
that the combination with EGFR inhibitor further increases cell killing. On the other hand, 
in hypoxia, Lim 1215 cells were quite resistant to MEK inhibition; however, at higher 
concentrations, it was possible to see some synergy between the combination of EGFR and 
MEK inhibition. This experiment suggests that Lim 1215 cells are more dependent on the 
MAPK pathway for their survival to EGFR inhibition in hypoxia, as the hypoxic-resistance 
phenotype can be reversed with this combination.  
 
Figure 14: EGFR and MEK inhibition intercept resistance to EGFR inhibition in hypoxia in WT4 CRC. 
Response of Lim 1215 cells to the combination of EGFR and MEK inhibitors. Lim cells were cultured with 
increasing concentrations of EGFR inhibitor gefitinib alone, MEk inhibitor Selumetinib or Trametinib alone, 
and their combination. Cells were incubated at 21% or 1% O2 for 10 days. All plates were seeded, fixed, 
stained and scanned at the same time. 
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Our findings explain why cells are able to resist EGFR inhibition in hypoxia, shed 
some light on how to reverse the resistance and have ruled out HIF, MET, RTK upregulation 
or acquisition of mutations in RAS and BRAF oncogenes as the cause for the resistance. 
However, the mechanism that leads to the activation of Ras in hypoxia still remains 
unknown.  
One possible explanation for the activation of RAS in hypoxia is by the increased 
secretion of cytokines in hypoxia,164,165 which could act on an autocrine manner and be 
activating a receptor, which in turn would lead to the activation of RAS. To test this 
hypothesis we performed a cytokine array in DiFi cells (Figure 15). We observed that several 
cytokines are upregulated in hypoxia and that this upregulation is maintained upon 
cetuximab treatment, which indicates that this hypothesis can be right. Further validation 
of this concept can be done using conditioned medium (from cells grown in hypoxia) in cells 
that will be cultured in normoxia to verify if the later become resistant to cetuximab due 
to soluble factors released to the media. Transcription analysis, as well as ELISA, of each of 
these soluble cytokines should also be performed in the experimental setting. This would 
validate our hypothesis but we would still need to find which are the most important 
cytokines for the resistance mechanism and how they are activating Ras. To do that we can, 
for example, knock-down/inhibit each of the cytokines that are upregulated in hypoxia and 
check if these cells are still more resistant to cetuximab in hypoxia or if the phenotype is 
reversed. Interestingly, some of these proteins —IL-8, CXCL1, VEGF— are known to be 
expressed on a NF-kB dependent manner,165–167 making this transcription factor an 
interesting target for future investigation. Given that VEGF is secreted by WT4 CRC cells in 
hypoxia, the use of anti-VEGF(R) drugs should also be considered in vitro. 
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Figure 15: Hypoxia increases the production of cytokines. 
Cytokine production in DiFi cells was analyzed using a cytokine array. The supernatant medium was collected 
48 hours after treatment with 1μg/mL of cetuximab. Hypoxic cells overproduce Cystatin C, CXCL1, IGFBP-3, 
IL-8, Lipocalin-2, CCL20, TTF3 and VEGF and this overproduction is maintained upon treatment. 
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2.2. Loss of function genetic screen in Lim 1215 cells 
In the second part of this project we used a more unbiased approach to find 
synthetic lethal interactions with hypoxia and also to find what can be driving resistance to 
EGFR inhibition in hypoxia. To do that, we analyzed the gene expression profile of six 
different WT4 CRC cell lines (Lim 1215, DiFi, OXCO2, CCK 81, C99 and HCA 46) cultured in 
hypoxia (and compared with normoxia condition). These results were crossed with data 
from WT4 CRC patient samples to make sure our in vitro signature had significance in a 
clinical context. We then derived a specific WT4 CRC hypoxia-signature, containing only the 
genes that overlapped in both data sets. We used this signature to build a shRNA library 
containing all the shRNAs that target these genes and used this library to perform a loss of 
function genetic screen in Lim 1215 cells. 
 If any of the genes present in our library are pivotal for the survival of WT4 CRC 
cells cultured under hypoxic conditions, cells that are knockdown (KD) for these genes 
should appear dropped in the whole cell population, when compared to the population of 
cells cultured in normoxia. After the analysis of the screen we identified 4 genes statistically 
significant as being synthetic lethal with hypoxia. We proceeded with the validation of this 
hits by KD these genes with individual shRNAs. By the end of this internship this validations 
was not yet completed. 
Similarly, if any of the genes present in this hypoxia library are pivotal for the 
survival of WT4 CRC cells cultured with cetuximab and under hypoxic conditions, cells that 
are KD for these genes should appear dropped in the cell population, when compared to 
the population of cells cultured without cetuximab under hypoxic conditions. After the 
analysis of the screen no hits were found. This can be explained by the fact that our library 
is relatively small (comprising only 107 genes) and also because it was designed mainly to 
find synthetic lethal interactions with hypoxia. To increase the chances of finding synthetic 
lethal hits with cetuximab/hypoxia, we should repeat the screen using a bigger library, for 
example, containing shRNAs that target all human kinases genes. 
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3. Conclusions and Future Perspectives  
In the first part of this work we showed that WT4 CRC cell lines are resistant to EGFR 
inhibition when cultured in hypoxia. These results are in concordance with two clinical trials 
(CAIRO2 and PACCE) which concluded that the combination of chemotherapy with anti-
EGFR and anti-VEGF drugs is not recommended for the treatment of mCRC in clinical 
practice.148,150 These trials’ results were unexpected given that both EGFR and VEGF are 
critical pathways in CRC pathogenesis,112,113,138,139 therefore providing a strong rationale for 
targeting these two pathways. Understanding why this combination is not being effective 
was the main goal of this first part of our work. Several EGFR resistance mechanisms have 
been already described in the literature; we tested all of them, but none validated in 
hypoxia, which brings novelty to this work and calls for more investigation. We have shown 
that the resistance phenotype is caused by the activation of Ras in hypoxia, however the 
mechanism behind this activation is still not known. Our last experiments point to the 
involvement of cytokines in this activation but more work is necessary to further elucidate 
on this. 
Our laboratory was a pioneer in the development of the technology to perform 
synthetic lethality genetic screens. We took advantage of this technology to try to answer 
our first question —what is causing the resistance to EGFR inhibition in hypoxia— using a 
more unbiased approach and also to look for novel synthetic lethal interactions with 
hypoxia. We performed a loss of function genetic screen in Lim 1215 cells. We identified 
four genes as potential candidates to be synthetic lethal with hypoxia. By the end of the 
internship the validation of these hits was still ongoing, so no results are presented in this 
thesis. We didn’t identify any genes as potential candidates to explain the resistance 
phenotype. 
Discovering the mechanism underlying the resistance to EGFR inhibition is of high 
biological significance and for this reason the project will be continued. The results of a 
future screen using a larger library should provide essential information to help unveiling 
the resistance mechanism of EGFR inhibition in hypoxia. Some biochemical experiments 
will follow to validate all colony formation assays (confirm the activity of the used drugs). 
To increase clinical significance of the project the resistance phenotype will be validated in 
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vivo. Moreover, RNAseq experiments will be conducted to elucidate about genes/cellular 
pathways whose overexpression/activation under hypoxia are maintained upon EGFR 
inhibition and thus can elucidate on the resistance mechanism.  
Finally, the ongoing validation of the hits found in the screen to be synthetic lethal 
with hypoxia should provide novel targets to exploit in combination with antiangiogenic 
therapies to increase therapeutic responses and reduce resistance. And in case these genes 
overlap with genes found on patients who respond to AA therapies (and don’t overlap with 
patients who don’t respond to AA therapies) they might serve as biomarkers for the 
selection of patients who may benefit from AA therapies. This is of great clinical 
significance, as so far no biomarkers of response to AA therapies have been found. 
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4. Materials and Methods 
4.1. Cell culture 
During this research project we used nine different cell lines; six are derived from 
WT4 CRC patients (Lim 1215, DiFi, OXCO2, CCK 81, C99 and HCA 46), two are derived from 
KRASMUT (LoVo) and BRAFMUT (HT-29) patients, and the other one is derived from human 
embryonic kidney cells (HEK-293T). Lim 1215 cells were used in all the assays performed 
during our project; DiFi, OXCO2, CCK 81, LoVo and HT-29 were used only in validation 
assays; and HEK-293T cells were used for lentivirus production. These cell lines were 
selected based on their genotype, culturing characteristics and, in the case of the CRC cells, 
also the ability to proliferate for at least 2 weeks in hypoxic conditions (1% O2). 
All cells were cultured at 37°C and with 5% CO2; the oxygen percentage in normoxia 
was 21% and in hypoxia 1%. The eight CRC cell lines were cultured in RPMI 1640 medium 
(Gibco) and HEK-293T cells were cultured in DMEM medium (Gibco). Both mediums were 
supplemented with: 10% Fetal Bovine Serum (Thermo Scientific), 1% 
Penicillin/Streptomycin (Gibco) and 1% L-Glutamine (Gibco). 
The list of drugs used throughout our project can be found in table 3.  
Table 3: List of drugs used during the project and their targets. 
Drug Name Target 
Cetuximab EGFR 
Gefitinib EGFR 
Neratinib EGFR and HER2 
MK2066 AKT 
GDC0441 PI3K 
Selumetinib ERK 
Trametinib ERK 
Crizotinib MET 
Digoxin HIF1α 
DMOG PHDs 
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4.2. Functional assays 
4.2.1. Long-term proliferation (colony formation) assays 
Cells were seeded (according to table 4) and placed in 21% or 1% O2 incubators 
overnight, to allow cell-attachment to the plates. Culture media (and drugs) were refreshed 
every 2-3 days. When control wells (wells not subjected to drugs) were confluent, cells 
were fixed using a solution of 2% formaldehyde in phosphate-buffered saline (PBS) for 2 
hours, after which they were stained, using a solution of 0.1% crystal violet in water for up 
to 10 minutes. The staining solution was removed, plates were washed with water and left 
to dry for 1 or 2 days, after which plates were scanned and stored. All experiments were 
repeated at least three times. 
Table 4: Cell seeding information 
Cell Line 
Cells seeded in   
6-well plates 
Cells seeded in 
12-well plates 
Cells seeded in 
96-well plates 
Lim 20000 10000 1500 
DiFi 40000 20000 2000 
LoVo 20000 10000 1500 
HT-29 20000 10000 1500 
CCK81 40000 20000 2000 
OXCO2 40000 20000 2000 
 
4.2.2. Western Blot 
Cells were washed with chilled PBS on ice, lysed with RIPA buffer (25mM Tris - HCl 
pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing protease 
inhibitors (Complete (Roche) and phosphatase inhibitor cocktails II and III (Sigma)) and 
proteins were extracted by incubating the samples for 30 min on ice, vortexing every 10 
minutes. Samples were then centrifuged for 10 minutes at 14.000 rpm at 4°C.  
Protein concentration was quantified by Bicinchoninic Acid (BCA) assay (Pierce BCA, 
Thermo Scientific). 50 µg of protein (denatured with DTT followed by 5 minutes heating at 
37 
 
95°C) was then loaded in a 4-12% polyacrylamide gel, being separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for approximately 90 minutes at 165 
volts. Proteins were transferred from the gel to a polyvinylidene fluoride (PVDF) 
membrane, using 330 mA for 90 minutes. Membranes were then placed in blocking 
solution (5% bovine serum albumin (BSA) in PBS with 0.1% Tween-20 (PBS-T). 
Subsequently, membranes were probed with primary antibody in blocking solution and left 
incubating overnight at 4 °C with constant shaking. Membranes were washed 3 times for 
10 minutes with PBS-T, followed by one hour incubation at room temperature with the 
second antibody (HRP conjugated, 1:10000) in blocking solution. Membranes were washed 
3 times for 10 minutes in PBS-T. Finally, the Western Blot was developed by adding a 
chemiluminescence substrate (ECL, Thermo Scientific) to the membranes, which was then 
detected using a ChemiDoc (Bio-Rad). The antibodies used in this project are listed in Table 
5. 
Table 5: List of antibodies used for western blot during the project. 
Target protein Molecular weight Isotype Brand 
EGFR 170 Mouse BD Biosciences 
EGFR p-Y1068 175 Rabbit Abcam 
HIF1α 120 Rabbit Cayman 
AKT 60 Rabbit Cell Signalling 
AKT p-S473 60 Rabbit Cell Signaling 
ERK 1/2 42, 44 Rabbit Santa Cruz 
ERK p-Y204 42, 44 Mouse Santa Cruz 
MET 140 Rabbit Cell Signalling 
MET p-Y1234/5 145 Rabbit Cell Signaling 
Cleaved PARP 89 Rabbit Cell Signalling 
Tubulin 55 Mouse Sigma 
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4.2.3. GTP-RAS pull down 
Cells were washed with chilled PBS on ice, lysed, incubated and centrifuged (see 
first paragraph of western blot). Protein concentration was quantified by BCA. 600 μg of 
protein was used to specifically pull down active Ras using an active Ras pull-down and 
detection kit (Thermo Scientific). After GTP-Ras pull down, samples were reduced and 
normal western blot protocol was followed. 
4.2.4. Phospho RTK array 
Cell lysates were diluted and incubated with the Human Phospho-RTK Array (R&D 
Systems), according to the kit’s instructions. After binding the extracellular domain of both 
phosphorylated and unphosphorylated RTKs, unbound material was washed away. A pan 
anti-phospho-tyrosine antibody conjugated to horseradish peroxidase (HRP) was used to 
detect phosphorylated tyrosines on activated receptors by chemiluminescence.  
4.2.5. Cytokine array 
Cell culture supernatant was diluted and incubated overnight with the Proteome 
Profiler Human XL Cytokine Array (R&D Systems), according to the kit’s instructions. The 
membranes were washed to remove unbound material followed by incubation with a 
cocktail of biotinylated detection antibodies. Streptavidin-HRP and chemiluminescent 
detection reagents were then applied, and a signal was produced at each capture spot 
corresponding to the amount of protein bound. 
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4.3. WT4 CRC hypoxia-specific library  
Six different WT4 CRC cell lines (Lim 1215, DiFi, OXCO2, CCK 81, C99 and HCA 46) 
were cultured for 3 days, in both normoxia and hypoxia, after which cells were collected in 
Trizol and handed in for RNA sequencing. Data was analyzed with the help of Andreas 
Schlicker (a bioinformatician from our laboratory) and a WT4 CRC hypoxia-specific 
signature was derived, containing the genes that were significantly overexpressed only in 
hypoxia (based in the RNAseq data) and that also overlapped with genes expressed in WT4 
CRC patients. The signature consists of 107 genes (Table 6). 
Table 6: Genes present in the WT4 CRC hypoxia-signature. 
# Gene 
Name 
Ensembl Gene ID # Gene 
Name 
Ensembl Gene ID # Gene 
Name 
Ensembl Gene ID 
1 ADRA2A ENSG00000150594 37 TNS1 ENSG00000079308 73 HIF3A ENSG00000124440 
2 ALOX5 ENSG00000275565 38 VLDLR ENSG00000147852 74 PDZD3 ENSG00000172367 
3 ALOX5 ENSG00000012779 39 PPFIA4 ENSG00000143847 75 SCIN ENSG00000006747 
4 AOAH ENSG00000136250 40 CYP4F2 ENSG00000186115 76 SYT8 ENSG00000149043 
5 ARNT ENSG00000143437 41 STC2 ENSG00000113739 77 AHNAK2 ENSG00000185567 
6 BNIP3 ENSG00000176171 42 BAIAP3 ENSG00000007516 78 ELFN2 ENSG00000166897 
7 C4BPB ENSG00000123843 43 CLIC3 ENSG00000169583 79 PRAP1 ENSG00000165828 
8 CA9 ENSG00000107159 44 SLC16A4 ENSG00000168679 80 LGI4 ENSG00000153902 
9 CACNA1C ENSG00000151067 45 GCNT3 ENSG00000140297 81 PSORS1C1 ENSG00000206458 
10 CALB1 ENSG00000104327 46 AKAP12 ENSG00000131016 82 LDHD ENSG00000166816 
11 CDA ENSG00000158825 47 AATK ENSG00000181409 83 SLC5A9 ENSG00000117834 
12 CKB ENSG00000166165 48 PLCH2 ENSG00000276429 84 CREG2 ENSG00000175874 
13 CNGA1 ENSG00000198515 49 KIAA0319 ENSG00000137261 85 UNC13D ENSG00000092929 
14 COL1A1 ENSG00000108821 50 MUC12 ENSG00000205277 86 GPR115 ENSG00000153294 
15 COL17A1 ENSG00000065618 51 MSLN ENSG00000102854 87 SLC29A4 ENSG00000164638 
16 CP ENSG00000047457 52 B3GALT5 ENSG00000183778 88 C11orf86 ENSG00000173237 
17 CYP1A1 ENSG00000140465 53 PNMA2 ENSG00000240694 89 GPR110 ENSG00000153292 
18 ARID3A ENSG00000116017 54 BTNL3 ENSG00000168903 90 SLC39A5 ENSG00000139540 
19 EDN1 ENSG00000078401 55 PADI2 ENSG00000117115 91 TMEM150B ENSG00000180061 
20 EDN2 ENSG00000127129 56 OBSL1 ENSG00000124006 92 ENTPD8 ENSG00000188833 
21 EFNA2 ENSG00000099617 57 CADM1 ENSG00000182985 93 KPNA7 ENSG00000185467 
22 EGR1 ENSG00000120738 58 FBXO2 ENSG00000116661 94 GABRE ENSG00000102287 
23 FABP1 ENSG00000163586 59 SRPX2 ENSG00000102359 95 CAPN14 ENSG00000214711 
24 FN1 ENSG00000115414 60 PADI1 ENSG00000142623 96 GABRE ENSG00000102287 
25 FOS ENSG00000170345 61 ANGPTL4 ENSG00000167772 97 PPP1R3G ENSG00000219607 
26 GABRE ENSG00000102287 62 PLAC8 ENSG00000145287 98 PDE4C ENSG00000105650 
27 HAS3 ENSG00000103044 63 KRT20 ENSG00000171431 99 FER1L4 ENSG00000088340 
28 IL6 ENSG00000136244 64 RHOF ENSG00000139725 100 PTPRR ENSG00000153233 
29 MGAT3 ENSG00000128268 65 RNF186 ENSG00000178828 101 REN ENSG00000143839 
30 MST1 ENSG00000173531 66 LEPREL1 ENSG00000090530 102 SPOCK1 ENSG00000152377 
31 MUC1 ENSG00000185499 67 TNFRSF19 ENSG00000127863 103 SULT2B1 ENSG00000088002 
32 CEACAM6 ENSG00000086548 68 PMEPA1 ENSG00000124225 104 TFF1 ENSG00000160182 
33 SERPINE1 ENSG00000106366 69 ALPK3 ENSG00000136383 105 TFF2 ENSG00000160181 
34 PCK1 ENSG00000124253 70 RRAGD ENSG00000025039 106 TFF3 ENSG00000160180 
35 PDE4C ENSG00000105650 71 ACE2 ENSG00000130234 107 TGFB3 ENSG00000119699 
36 PPP1R3C ENSG00000119938 72 PRSS22 ENSG00000005001    
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Based on this signature, we built a library containing all the shRNAs that target the 
genes present in this signature. The shRNA vectors were purchased from the “The RNAi 
Consortium” (TRC). 
4.3.1. Library picking 
To build the library we picked E.coli bacteria (from the whole genome TRC library - 
stored at -80 °C in glycerol stocks), which contain a pLKO vector with an insert of the desired 
shRNA and also an antibiotic resistance marker. Bacteria were cultured overnight at 37 °C 
in 2X LB medium (20g of Bacto-Tryptone, 10g of yeast extract, 10g of NaCl in 1L of water) 
with carbenicillin. Plasmid DNA was isolated from the bacteria using a standard DNA 
isolation protocol (from Roche), after which the DNA concentration was measured (using a 
Nanodrop ND1000 system).  
4.3.2. Lentivirus preparation 
The lentivirus was prepared by transfecting HEK-293T cells with plasmid DNA from 
the shRNA library. To do that, we mixed 1 µg of plasmid DNA of our library, 1 µg of lentivirus 
packaging mix (pMD2.G envelope plasmid and pMDLg/pRRE packaging plasmid) and 6 µL 
of polyethylenimine (PEI) in 100 µL DMEM medium (quantities used in a 6-well plate 
setting). The mix was vortexed briefly, incubated for 15 minutes at room temperature and 
added to one million HEK-293T cells seeded the day before in 2 mL of DMEM medium. Cells 
were incubated overnight; the next day the medium was refreshed; after 48 hours of 
incubation, the medium containing the lentivirus was filtered (by 20-μm filters), collected 
and stored at -80°C. 
4.3.3. Loss of function pooled shRNA screen 
Lim 1215 cells were seeded and infected with the lentivirus containing library, using 
a complexity of 2000-fold (which means that each shRNA from the library has to be present 
in at least 2000 cells) and a multiplicity of infection (MOI) of approximately 0.3 (to make 
sure cells are infected with only one lentivirus, delivering only one shRNA; this is very 
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important because multiple integrations would lead to confounding results due to 
passenger effect). 24 hours after the infection we started the selection of the cells that got 
infected by adding puromycin (1 μL/mL) to the medium. When the selection was finished 
(to know this, when we start puromycin selection we also add puromycin to cells that didn’t 
receive any lentivirus and therefore aren’t resistant to antibiotic – when these cells are all 
dead it means the selection is finished), cells were trypsinized and reseeded according to 
the layout of the screen – figure 16. 
Cells were seeded in three technical replicates for each of the five arms: time-point 
zero (cells at the day of seeding, to allow selecting for straight lethal hits), 21% O2 treated 
and untreated and 1% O2 treated and untreated. Media was refreshed every 2-3 days. After 
1 and 2 weeks the untreated and treated arms were collected, respectively. Genomic DNA 
was isolated using DNeasy Blood & Tissue Kit (Qiagen), according to manufacturer’s 
protocol and viral DNA recovered by PCR.  
PCRs were performed, to add barcodes to the different replicates in order to 
identify them after sequencing. Samples were purified using High Pure PCR Product 
Purification Kit (Roche), according to manufacturer’s protocol. A 1% agarose gel in 0.5x TBE 
was run (with 4 µl of PCR product) to confirm PCR amplification. Purified PCR products were 
analyzed by deep sequencing to identify the number of shRNA inserts present in the cell 
population. 
 
Figure 16: Synthetic lethality screen layout. 
In this screen cells are seeded in three technical replicates in each arm, to increase the statistical relevance 
of the results. Also, a time point zero (T0) is included, as a reference of comparison. To find synthetic lethal 
interactions with hypoxia, cells are cultured for one week at 21% and 1% O2. To find out genes involved in the 
resistance to cetuximab, cells are cultured for two weeks with cetuximab (5μg/mL) at 21% and 1% O2. 
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